| [1] 沈耿杨,任辉,张志达,等.龟板联合阿伦磷酸钠对激素性骨质疏松大鼠腰椎Runx2、CTSK表达的影响[J].中华中医药杂志, 2017, 32(5):2181-2185.[2] Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.ANN RHEUM DIS. 2002;61:32-36.[3] van Staa TP,Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int.2002;13:777-787.[4] Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J BONE MINER RES.2004;19:893-899.[5] Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid- induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319-1328.[6] Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J BONE MINER RES. 2000;15:993- 1000.[7] Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. GENE. 2004;341:19-39.[8] Galli C, Passeri G, Macaluso GM. Osteocytes and WNT: the mechanical control of bone formation. J DENT RES. 2010;89: 331.[9] Wang Y, Li YP, Paulson C, et al. Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed). 2014;19:379.[10] Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol. 2015;11(2): 98-109.[11] Shi C, Huang P, Kang H, et al. Glucocorticoid inhibits cell proliferation in differentiating osteoblasts by microRNA-199a targeting of WNT signaling. J Mol Endocrinol. 2015;54: 325-337.[12] Chen Z, Xue J, Shen T, et al. Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway. Int J Mol Med.2016;37:329-338.[13] Ke HZ, Richards WG, Li X, et al. Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases. Endocr Rev. 2012; 33(5):747-783.[14] Guanabens N, Gifre L, Peris P. The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis. CURR OSTEOPOROS REP. 2014;12:90-97.[15] Hayashi K, Yamaguchi T, Yano S, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2009;379(2):261-266.[16] Ke HZ, Richards WG, Li X, et al. Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases. Endocr Rev. 2012; 33: 747-783.[17] 任辉.龟板防治GIOP中miRNA调控Wnt/β-catenin通路的机理研究[D] 广州:广州中医药大学博士论文,2017.[18] Liu MJ, Li Y, Pan JH, et al. Effects of zuogui pill (see text) on Wnt singal transduction in rats with glucocorticoid-induced osteoporosis. J Tradit Chin Med. 2011;31(2):98-102.[19] Ren H, Liang D, Jiang X, et al. Variance of spinal osteoporosis induced by dexamethasone and methylprednisolone and its associated mechanism. Steroids. 2015;102:65-75.[20] Shen G, Ren H, Qiu T, et al. Effect of glucocorticoid withdrawal on glucocorticoid inducing bone impairment. Biochem Biophys Res Commun.2016;477:1059-1064.[21] Zhang Z, Ren H, Shen G, et al. Animal models for glucocorticoid-induced postmenopausal osteoporosis: An updated review. Biomed Pharmacother.2016;84:438-446.[22] 崔健超,杨志东,江晓兵,等.糖皮质激素性骨质疏松症的中医证型分布特点[J].中国骨质疏松杂志,2016,22(2):217-220.[23] 任辉,张志达,梁德,等.龟板改善激素性骨质疏松大鼠骨量、骨微细结构、骨生物力学和骨代谢的机制探讨[J].中华中医药杂志, 2016,31(5):1858-1862.[24] 王剑,郑洪新,刘瑞辉,等.补肾中药复方对糖皮质激素性骨质疏松症大鼠骨和肾组织Dlx5 mRNA及蛋白表达的影响[J].中华中医药杂志,2012,27(4):951-956.[25] 孙平,王金枝,刘丰,等.中药复方护骨胶囊治疗糖皮质激素性骨质疏松症[J].实用医学杂志, 2016,32(24):4122-4124.[26] 查小云,胡予.骨质疏松相关信号通路研究进展[J].中国骨质疏松杂志,2014,20(2):205-209.[27] MacDonald BT, Joiner DM, Oyserman SM, et al. Bone mass is inversely proportional to Dkk1 levels in mice.Bone. 2007; 41(3):331-339.[28] 蔡建平,张贤,夏树林,等.杜仲对去势大鼠股骨重、矿物含量、胫骨抗弯力及血清碱性磷酸酶的影响[J].时珍国医国药,2009,20(8): 1967-1969. |
